Roberta D Ernst

Title: Roberta D. Ernst: Innovator in Enzyme Immunoassay Technologies

Introduction

Roberta D. Ernst is a distinguished inventor based in Mountain View, California, recognized for her contributions to the field of immunoassays. With two patents to her name, her innovative work has the potential to advance diagnostic techniques in medical science.

Latest Patents

Roberta D. Ernst's latest patents reflect her expertise in enzyme-polyidothyronine conjugates. Her first patent details an enzyme-bound-polyidothyronine conjugate designed for immunoassay applications. This conjugate is created with an enzyme that can be reversibly deactivated by polyiodothyronine and reactivated by an antibody binding to it. Preferred enzymes for this technology include malate dehydrogenase and triose phosphate isomerase.

The second patent focuses on a method for determining physiological amounts of polyiodothyronine in bodily fluids, especially serum. It outlines a homogeneous enzyme immunoassay that utilizes an enzyme-bound-polyidothyronine, which retains less than 50 percent of its original enzyme activity. This activity can increase upon binding with a receptor, allowing for accurate measurement of polyiodothyronine levels when compared to known standards.

Career Highlights

Roberta is affiliated with Syva Company, a firm specializing in innovative diagnostic solutions. Her role at Syva has allowed her to develop cutting-edge immunoassay technologies that improve the detection and quantification of biomolecules in clinical samples.

Collaborations

Throughout her career, Roberta D. Ernst has collaborated with colleagues such as Judith I. Blakemore and Richard K. Leute. These partnerships have bolstered her research efforts and contributed to the advancement of diagnostic methodologies in medical science.

Conclusion

Roberta D. Ernst's innovative contributions to enzyme immunoassays mark her as a significant figure in the medical diagnostics field. Her patents not only enhance our understanding of polyiodothyronine but also improve the tools available for physicians in diagnosing various health conditions. As she continues her work at Syva Company, her impact on the field is expected to grow, inspiring future developments in immunoassay technologies.